65645-52-5

Usage

Uses

Used in Pharmaceutical Industry:
5-methoxypyridin-3-amine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of drugs, enhancing their therapeutic properties and efficacy.
Used in Agriculture:
5-methoxypyridin-3-amine is used as a chemical building block in the development of agrochemicals, contributing to the creation of new pesticides or fertilizers that can improve crop yield and protection against pests.
Used in Materials Science:
5-methoxypyridin-3-amine is utilized as a component in the formulation of advanced materials, such as polymers and composites, due to its potential to influence the physical and chemical properties of these materials, leading to innovative applications in various industries.

InChI:InChI=1/C9H10N2O4/c1-2-15-9(12)5-7-3-4-10-6-8(7)11(13)14/h3-4,6H,2,5H2,1H3

Upstream product

• 54415-82-6 4-bis(ethoxycarbonyl)methyl-3-nitropyridine 
• 626-64-2 pyridin-4-ol 
• 5435-54-1 4-hydroxy-3-nitropyridine 
• 13091-23-1 4-chloro-3-nitropyridine 
• 65645-51-4 ethyl 2-(3-nitropyridin-4-yl)-3-oxobutanoate 
• 2530-26-9 3-nitropyridine 
• 105-39-5 chloroacetic acid ethyl ester 
• 932702-14-2 1-(tert-butyl) 3-ethyl 2-(3-nitropyridin-4-yl)malonate 

Downstream Products

• 65645-57-0 ethyl 2-(3-aminopyridin-4-yl)acetate 
• 1338219-56-9 ethyl {3-[(tert-butoxycarbonyl)amino]pyridin-4-yl}acetate 
• 486422-87-1 tert-butyl [4-(2-hydroxyethyl)pyridin-3-yl]carbamate 
• 1637752-28-3 spiro[cyclopropane-1,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 

Relevant academic research and scientific papers

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion

RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH; R1A is C1-C3alkyl, C1-C3haloalkyl C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independently selected from C1- C3alkyl, halo, amino and C1-C3alkoxy; the two R1B together with the carbon atom to which they are attached combine and form C3-C6cycloalkyl or heterocyclyl, wherein the cycloalkyl is substituent with C(=O)OR1C, NHC(=O)OR1C or NHS(=O)2R1C, and the heterocyclyl is substituent with C(=O)R1C, C(=O)OR1C, S(=O)2 R1C, C(=O)NH2 or C(=O)NR1CR1C'; n is 0, 1 or 2; n, q, R1C, R1C', R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH, R1A is C1-C3alkyl, C1-C3haloalkyl, C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independently selected from C1- C3alkyl, halo, amino and C1-C3alkoxy; the two R1B together with the carbon atom to which they are attached combine and form C3- C6cycloalkyl or heterocyclyl, wherein the cycloalkyl is substituent with C(=O)OR1C, NHC(=O)OR1C or NHS(=O)2 R1C, and the heterocyclyl is substituent with C(=O)R1C, C(=O)OR1C, S(=O)2 R1C, C(=O)NH2 or C(=O)NR1CR1C'; q, n, R1C, R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): (Formula I), wherein Z1 is NR1A, CHR1A or CR1BR1B; one of Z2 and Z3 is CH or CR1A', the other is N, CH or CR1A'; n is 0, 1 or 2; q is 0, 1 or 2; R1A, R1A', R1B, R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS

The invention concerns novel substituted spiro urea azetidinyl or piperidinyl compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention furth

RSV ANTIVIRAL COMPOUNDS

Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R22, W, Q, V, Z p,s,and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.

PHARMACEUTICAL COMPOUNDS

Benzimidazoles of formula (I): wherein: A is 5-to 12-membered aryl or 5-to 12-membered heteroaryl, each of which is unsubstituted or substituted; Y is a single bond, -(CH2)p-, -X-, -CH2-X-, or -X-CH2-; X is -O-, -S-, -N(R2)-, >C=O, >S(=O), >S(=O)2, -O-C(=O)-, -C(=O)-O-, N(R2)-C(=O)-, or -C(=O)-N(R2)-; each L is independently a single bond, C1-3alkylene, C2-3alkenylene or C2-3alkynylene; R1is C1-6alkyl, C2-6alkenyl or C2-6alkynyl, each of which is unsubstituted or substituted; each Z is independently -N(R2)2, -OR2, -SR2, -S(=O)R2, -S(=O)2R2; each R2 is independently hydrogen, C1-6alkyl, C2-6alkenyl or C2-6 alkynyl, wherein said alkyl, alkenyl and alkynyl groups are unsubstituted or substituted; m is 0, 1, 2, or 3; n is 1, 2, or 3; and p is 1, 2, or 3; and the pharmaceutically acceptable salt thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors

The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.